Ovarian Cancer Coverage from Every Angle

2019 ASCO-SITC Symposium: IL-12 Plasmid Plus Neoadjuvant Chemotherapy in Ovarian Cancer

By: Cordi Craig
Posted: Wednesday, March 6, 2019

The addition of GEN-1, an interleukin-12 (IL-12) plasmid formulated with polyethyleneglycol-polyethyleneimine-cholesterol lipopolymer, to taxane and carboplatinum appeared to be safe and active among patients with epithelial ovarian cancer receiving neoadjuvant therapy, according to a study presented at the 2019 American Society of Clinical Oncology–Society for Immunotherapy of Cancer (ASCO-SITC) Clinical Immuno-Oncology Symposium in San Francisco (Abstract 2). Premal H. Thaker, MD, MS, of Washington University at St. Louis, and colleagues noted that although dose-limiting toxicity was not reached in this study, dose-escalation and safety profiles are being evaluated in an ongoing phase I/II study.

The study authors enrolled 18 patients with newly diagnosed epithelial ovarian cancer who had never received prior therapies. Of them, 12 received all 8 treatments with no dose-limiting toxicities, and 14 patients underwent interval debulking surgery.

GEN-1 appeared to be active and well tolerated among patients receiving neoadjuvant therapy. Prior to interval debulking surgery, the authors observed complete responses among 2 patients, partial responses in 10 patients, and stable disease in 2 patients. Of the 14 patients who underwent interval debulking surgery, residual disease was reported as R0 in 9 patients, R1 in 3 patients, and R2 in 2 patients. Pathologic response after interval debulking surgery was classified as complete pathologic response (n = 1), macroscopic (n = 7), and microscopic (n = 6).

The most common treatment-related toxicities were grade 1 nausea, abdominal pain, and fatigue. A single patient presented with grade 2 fevers associated with GEN-1 treatment but responded to acetaminophen and fluids.

Disclosure: The study authors’ disclosure information may be found at coi.asco.org.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.